LID Lidco Group Plc

TIDMLID

LiDCO Group Plc

07 November 2019

LiDCO Group Plc

("LiDCO" or the "Company")

LiDCO to present at Mello London, 2019

LiDCO (AIM: LID), the hemodynamic monitoring company, is pleased to announce that the Company will be attending the Mello London, 2019 investor conference taking place on Tuesday 12th & Wednesday 13th November 2019 to be held at the Clayton Hotel Chiswick, Chiswick High Road, London, W4 5RY.

Matt Sassone, Chief Executive Officer of LiDCO, will be presenting to delegates on Tuesday 12th November 2019.

For further information on the Mello London conference, please visit the event website https://melloevents.com/

For further information, please contact:

 
 LiDCO Group Plc                                                       www.lidco.com 
 Matt Sassone (CEO)                                         Tel: +44 (0)20 7749 1500 
 Tim Hall (CFO) 
 
 finnCap                                                    Tel: +44 (0)20 7600 1658 
 Geoff Nash / Hannah Boros (Corporate 
  Finance) 
 Andrew Burdis (Corporate Broking) 
 
 Walbrook PR Ltd                          Tel: 020 7933 8780 or lidco@walbrookpr.com 
 Paul McManus                                                     Mob: 07980 541 893 
 Lianne Cawthorne                                                 Mob: 07584 391 303 
 
 

About LiDCO Group Plc (www.lidco.com)

LiDCO is a supplier of non-invasive and minimally invasive hemodynamic equipment to hospitals used to monitor the amount of blood flowing around the body and ensure that vital organs are adequately oxygenated. LiDCO's products facilitate the application of hemodynamic optimisation protocols for high risk patients in both critical care units and in the operating theatre.

Increasingly clinical studies have shown that the optimisation of patients' hemodynamic status in high risk patients produces better outcomes and reduced hospital stay. LiDCO's computer-based technology, developed originally at St Thomas' Hospital in London, has been shown to significantly reduce morbidity and complications, length of stay and overall costs associated with major surgery.

Key Products:

LiDCOunity: a hemodynamic monitor that combines the full suite of LiDCO technology (non-invasive, minimally invasive and calibrated technologies) into one platform. Designed to have the flexibility to adapt to a patient's changing acuity, the product enables clinicians to seamlessly transition between non-invasive, minimally invasive and calibrated hemodynamic monitoring.

LiDCOplus: a computer-based platform monitor used in the Intensive Care Unit for real-time continuous display of hemodynamic parameters including cardiac output, oxygen delivery and fluid-volume responsiveness (PPV% and SVV%).

LiDCOrapid: a cardiac output monitor designed specifically for use in the operating theatre for fluid and drug management. The monitor enables anaesthetists to receive accurate and immediate feedback on the patient's fluid and hemodynamic status - a key measure of overall well-being before, during and after surgery. The LiDCOrapid provides:

-- early and rapid warning of hemodynamic change to aid choice of therapeutic route: fluid or drug

-- quantification of hemodynamic response guidance on effective delivery of fluids to ensure the right amount at the right time

The software incorporated into LiDCOrapid allows the LiDCOrapid monitor to co-display Medtronic's level of consciousness parameter ('BIS(TM') )* and add the convenience of CNSystem's continuous non-invasive blood pressure monitoring ('CNAP')**. This addresses a growing requirement for non-invasive monitoring solutions that are more comprehensive and can effectively replace multiple single parameter monitors.

LiDCOview: an easy-to-use graphical display of historical LiDCOplus and LiDCOrapid hemodynamic data.

*BIS(TM) and Bispectral Index are trademarks of Medtronic registered in the US and foreign countries.

**CNAP(TM) is a trademark of CNSystems Medizintechnik AG.

LiDCO monitors use single-patient disposables (sensors or smartcards) which provide an ongoing revenue stream.

LiDCO Distribution Network:

LiDCO sells directly to hospitals in the UK and USA and through a network of specialty critical care and anaesthesia distributors in the rest of the world.

LiDCO's headquarters are in London and its shares are traded on AIM.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

END

NRALLFFILLLDIIA

(END) Dow Jones Newswires

November 07, 2019 05:30 ET (10:30 GMT)

Grafico Azioni Lidco (LSE:LID)
Storico
Da Mar 2024 a Apr 2024

Grafico Azioni Lidco (LSE:LID)
Storico
Da Apr 2023 a Apr 2024